MD Referral: How ClinOne Enrolled ~400 Patients for Oncology Trial in Only 10 Months
Today we give a case study on ClinOne MD Referral, and how it’s worked to achieve enrollment goals — and even exceed them — when implemented in a global study.
Background: An existing ClinOne client enabled MD Referral to provision a global phase II study across the U.S., Europe, and Australia and their results far surpassed expectations. The sponsor’s aggressive objective to randomize 400 patients diagnosed with a rare oncology disease within 15 months, with ClinOne’s solution, dramatically exceeded this goal.
- 17,939 globally-located healthcare specialists from ClinOne’s MD Referral network were selected, including: oncologists, hematologists and a small number of other specialists.
- Every site, on average, had 54 highly-engaged referring specialists within a 50-mile radius of each research site (from 5 to 205 highly-engaged providers per site).
- ClinOne’s MD Referral network was highly-engaged within this study, and in line with the overall performance average of 24.7% for high engagement.
- High engagement rates among the European network providers led the U.S. sites by 12%, displaying higher degrees of interest among the specialists in the study and patient referral opportunities.
- By enabling ClinOne’s MD Referral, enrollment rates in the U.S. were 56% greater than sites in Australia where it was not enabled.
- Resulting enrollment rates throughout the 10-month period revealed that ClinOne’s MD Referral technology increased patient randomizations from 21 patients at the beginning of enabling the technology to 377 enrolled patients during the following 10 months, (5 months prior to their goal).
- ClinOne’s MD Referral application successfully achieved the sites’ enrollment performance goals, with only 1 center failing to recruit a single patient.
- MD Referral positively impacted enrollment by accelerating recruitment and the success of the trial, ultimately to provide a new treatment option aimed towards a cure.